secretaria.seprot@gmail.com
flagEspañol
flagEnglish
Facebook
Twitter
SEPROT
  • CURSOS Y CONGRESOS
  • TRABAJO
  • BECAS
  • PUBLICACIONES
  • QUIÉNES SOMOS
  • SOCIOS

Article: Multiomics Profiling of Alzheimer’s Disease Serum for the Identification of Autoantibody Biomarkers. R Barderas’s Lab (ISCIII)

21 October, 2021Articulos Socios SEProt, Newsadmin

Multiomics Profiling of Alzheimer’s Disease Serum for the Identification of Autoantibody Biomarkers
Pablo San Segundo-Acosta, Ana Montero-Calle, August Jernbom-Falk, Miren Alonso-Navarro, Elisa Pin, Eni Andersson, Cecilia Hellström, MariCruz Sánchez-Martínez, Alberto Rábano, Guillermo Solís-Fernández, Alberto Peláez-García, Javier Martínez-Useros, María Jesús Fernández-Aceñero, Anna Månberg, Peter Nilsson, and Rodrigo Barderas

Journal of Proteome Research (2021); DOI: 10.1021/acs.jproteome.1c00630

Abstract:

New biomarkers of Alzheimer’s disease (AD) with a diagnostic value in preclinical and prodromal stages are urgently needed. AD-related serum autoantibodies are potential candidate biomarkers. Here, we aimed at identifying AD-related serum autoantibodies using protein microarrays and mass spectrometry-based methods. To this end, an untargeted complementary screening using high-density (42,100 antigens) and low-density (384 antigens) planar protein-epitope signature tag (PrEST) arrays and an immunoprecipitation protocol coupled to mass spectrometry analysis were used for serum autoantibody profiling. From the untargeted screening phase, 377 antigens corresponding to 338 proteins were selected for validation. Out of them, IVD, CYFIP1, and ADD2 seroreactivity was validated using 128 sera from AD patients and controls by PrEST-suspension bead arrays, and ELISA or luminescence Halotag-based bead immunoassay using full-length recombinant proteins. Importantly, IVD, CYFIP1, and ADD2 showed in combination a noticeable AD diagnostic ability. Moreover, IVD protein abundance in the prefrontal cortex was significantly two-fold higher in AD patients than in controls by western blot and immunohistochemistry, whereas CYFIP1 and ADD2 were significantly down-regulated in AD patients. The panel of AD-related autoantigens identified by a comprehensive multiomics approach may provide new insights of the disease and should help in the blood-based diagnosis of Alzheimer’s disease. Mass spectrometry raw data are available in the ProteomeXchange database with the access number PXD028392..

Enlace: DOI:10.1021/acs.jproteome.1c00630

Previous post Article: Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer’s disease. E Santamaría’s Lab (UPNA-IdiSNA) Next post VII Meeting for young proteomics researchers

ESTAMOS EN

Facebook
Twitter

LO ÚLTIMO

  • VII Meeting for young proteomics researchers
  • Article: Multiomics Profiling of Alzheimer’s Disease Serum for the Identification of Autoantibody Biomarkers. R Barderas’s Lab (ISCIII)
  • Article: Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer’s disease. E Santamaría’s Lab (UPNA-IdiSNA)

OFERTAS DE TRABAJO

  • Postdoc SUMO & Ubiquitin in the Cell Cycle – Leiden University Medical Center
  • Postdoc functional proteomics and cell signaling, Blagoy-Blagoev Lab, SDU – Denmark
  • Postdoc at MC Durán Lab, INIBICA-UCA, Cádiz

CURSOS Y CONGRESOS

  • VII Meeting for young proteomics researchers
  • Weminar: Infection Medicine, New-old approaches & perspectives

CONTACT

Sociedad Española de Proteómica C/. Jaime Roig 11 46010 Valencia
secretaria@seprot.es

ESTAMOS EN

Facebook
Twitter

SOCIAL NETWORKS

Facebook
Twitter

ARCHIVO

Desde 2005…

NEWS

  • VII Meeting for young proteomics researchers
  • Article: Multiomics Profiling of Alzheimer’s Disease Serum for the Identification of Autoantibody Biomarkers. R Barderas’s Lab (ISCIII)
  • Article: Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer’s disease. E Santamaría’s Lab (UPNA-IdiSNA)

LINKS

ProteoRed precarios
Aviso Legal | Diseño Prisma
Esta web utiliza cookies para mejorar su experiencia Acepto Leer más
Política de cookies

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT